PrismRA®

Scipher Medicine Announces Publication of Real-World Study Demonstrating Clinical Utility of PrismRA® Blood Test

Retrieved on: 
Tuesday, February 1, 2022
General Health, Science, Health, Research, Joint, Molecular diagnostics, Patient, Health, University, Immunology, RA, Trial of the century, Rheumatoid arthritis, Twitter, Arthritis, Adoption, Woman, Autoimmunity, Degenerative disease, Man, Disease, TNF inhibitor, Precision medicine, Bone erosion, Arthritis Foundation, Stanford University, Time, University of Alabama, Texas Health Presbyterian Hospital Dallas, Division, FDA, Inflammation, Therapy, LinkedIn, Stanford University School of Medicine, Sickle Cell Anemia, a Molecular Disease, AIMS, Solution, Pharmaceutical industry, Rheumatology, Facebook, Medicine, PrismRA®, Scipher Medicine®, PRISMRA®, SCIPHER MEDICINE®

PrismRA is the only blood test in the market informing personalized treatment decisions for patients with RA.

Key Points: 
  • PrismRA is the only blood test in the market informing personalized treatment decisions for patients with RA.
  • According to the study, patients whose treatment was guided by PrismRA experienced three times better clinical response compared to patients whose therapy selection was not guided by PrismRA results.
  • Study results also suggest that PrismRA has high clinical utility, providing individualized patient information that guided physician therapy selection in 74% of patients.
  • PrismRA is a revolutionary blood test bringing precision medicine to the treatment of rheumatoid arthritis, which affects 20 million patients globally.

Nearly 15% of Prescribing U.S. Rheumatologists Use Scipher Medicine’s PrismRA® Blood Test Since Its Launch A Year Ago

Retrieved on: 
Monday, December 6, 2021
Biotechnology, Pharmaceutical, Health, Medical Devices, Patient, Man, Degenerative disease, Rheumatology, Bone erosion, Multiple sclerosis, Woman, MD, Rheumatoid arthritis, Precision medicine, Autoimmunity, TNF inhibitor, Solution, RA, Therapy, Arthritis, Physician, Medicine, Arthritis Foundation, Twitter, Ulcerative colitis, Health, HIV disease progression rates, FDA, Inflammation, Sickle Cell Anemia, a Molecular Disease, LinkedIn, Joint, Quality of life, Pharmaceutical industry, PrismRA®, Scipher Medicine®, PRISMRA®, SCIPHER MEDICINE®

PrismRA is the only blood test in the market informing personalized treatment decisions for patients with rheumatoid arthritis (RA).

Key Points: 
  • PrismRA is the only blood test in the market informing personalized treatment decisions for patients with rheumatoid arthritis (RA).
  • PrismRA identifies patients unlikely to respond to TNFi drugs, enabling non-responders to be prescribed alternative FDA-approved therapy from day one that could significantly improve clinical outcomes.
  • Rheumatologists, their patients, and healthcare stakeholders are responding very positively to PrismRA, said Sam Asgarian, M.D., chief medical officer of Scipher Medicine.
  • PrismRA is a revolutionary blood test bringing precision medicine to the treatment of rheumatoid arthritis, which affects 20 million patients globally.

Scipher Medicine Appoints Dr. Michael Elliott to its Science Advisory Board

Retrieved on: 
Thursday, December 2, 2021
Health, Medical Devices, Research, Science, Pharmaceutical, Cardiology, Biotechnology, Patient, Degenerative disease, Publication, Autoimmune disease, Ustekinumab, MBBS, Rheumatoid arthritis, Precision medicine, Johnson & Johnson, Doctor of Philosophy, University, TNF inhibitor, Solution, RA, Therapy, Physician, Infliximab, Medicine, Twitter, Kennedy Institute, Spectra, Royal college, Sickle Cell Anemia, a Molecular Disease, LinkedIn, Multimedia, Drug development, Royal Australasian College, TNF, Janssen Pharmaceuticals, Pharmaceutical industry, Scipher Medicine®, PrismRA®, SCIPHER MEDICINE®, PRISMRA®

Scipher Medicine , a precision immunology company matching patients with their most effective therapy, today announced the appointment of Michael Elliott, MBBS, PhD, FRACP, as scientific advisor.

Key Points: 
  • Scipher Medicine , a precision immunology company matching patients with their most effective therapy, today announced the appointment of Michael Elliott, MBBS, PhD, FRACP, as scientific advisor.
  • Im excited to join Scipher Medicine and support its important mission to match patients with their most effective therapy, said Dr. Elliott.
  • Fast forward to today, Scipher Medicine is ushering in a new era using its Spectra platform to enable precision medicine across several autoimmune diseases.
  • We are thrilled to welcome Dr. Elliott to our science advisory board, said Alif Saleh, Chief Executive Officer of Scipher Medicine.

RxParadigm Partners with Scipher Medicine® to Support Medication Utilization, Improve Patient Outcomes, and Lower Costs for Rheumatoid Arthritis Care

Retrieved on: 
Monday, November 15, 2021
Biotechnology, Pharmaceutical, Health, Medical Devices, Health, Intelligence, Drug utilization review, Pharmacy, Ulcerative colitis, Joint, CEO, Multiple sclerosis, TNF inhibitor, RA, PBM, Plasma protein binding, Rheumatoid arthritis, Multimedia, Arthritis Foundation, Medicine, Woman, Partnership, Twitter, Arthritis, Inflammation, LinkedIn, Therapy, Degenerative disease, Precision medicine, Physician, Autoimmunity, Sickle Cell Anemia, a Molecular Disease, Patient, FDA, Man, Pharmaceutical industry, PrismRA®, Scipher Medicine®, RxParadigm, PRISMRA®, SCIPHER MEDICINE®, RXPARADIGM

PrismRA is the only molecular signature blood test available in the U.S. that informs personalized treatment decisions for patients with rheumatoid arthritis (RA).

Key Points: 
  • PrismRA is the only molecular signature blood test available in the U.S. that informs personalized treatment decisions for patients with rheumatoid arthritis (RA).
  • PrismRA tests for patient response and enables them to start more effective FDA-approved therapies from the outset.
  • Scipher Medicines health economic analyses suggest that integrating PrismRA into the care pathway for patients with RA improves outcomes while decreasing drug and other medical costs.
  • "PrismRA empowers pharmacy benefit managers to guide and optimize drug utilization, which improves patient outcomes and lowers costs.

Trellis Rx Furthers Commitment to Advancing the Specialty Pharmacy Practice and Patient Outcomes with Integration of Scipher Medicine® PrismRA® Precision-Medicine Technology into Clinical Pathways

Retrieved on: 
Tuesday, October 12, 2021
Data Management, Practice Management, Technology, Managed Care, Other Health, Health, General Health, Pharmaceutical, Medical Devices, Software, Hospitals, Twitter, Risk, Degenerative disease, Protocol, Sickle Cell Anemia, a Molecular Disease, RA, LinkedIn, HIV disease progression rates, Precision medicine, TNF inhibitor, Rheumatoid arthritis, TNF, Therapy, Methotrexate, Partnership, Intelligence, Patient, Technology, Trellis, Pharmaceutical industry, Medical imaging, Trellis Rx, PrismRA®, Scipher Medicine®, TRELLIS RX, PRISMRA®, SCIPHER MEDICINE®

Scipher Medicine, the manufacturer of PrismRA, is a precision immunology company helping providers determine the most effective therapy for their patients.

Key Points: 
  • Scipher Medicine, the manufacturer of PrismRA, is a precision immunology company helping providers determine the most effective therapy for their patients.
  • Incorporating PrismRA into our clinical protocols directly supports our focus on improving outcomes while reducing the cost of care.
  • We are proud to be collaborating with a technology-driven company like Trellis Rx to advance patient outcomes through PrismRA testing, said Alif Saleh, Scipher Medicine CEO.
  • Trellis Rxs high-touch care model and evidence-based clinical protocols have enabled its partner health systems to drive market-leading clinical results for patients with rheumatoid arthritis.

Scipher Medicine™ Announces Publication of Clinical Study Validating PrismRA®, a Blood Test Predicting Non-Response to TNF Inhibitor Therapies in Patients with Rheumatoid Arthritis

Retrieved on: 
Tuesday, July 28, 2020
Data management, Biotechnology, Technology, Health, Pharmaceutical, Research, Software, Nanotechnology, Genetics, Science, Clinical trials, Medical specialties, Clinical medicine, Medicine, RTT, Rheumatology, Immunosuppressants, Autoimmune diseases, Disease-modifying antirheumatic drug, Rheumatoid arthritis, TNF inhibitor, Arthritis, Methotrexate, PrismRA®, Scipher Medicine

The publication titled Clinical validation of a blood-based predictive test for stratification of response to tumor necrosis factor inhibitor therapies in rheumatoid arthritis patients was published in Network and Systems Medicine .

Key Points: 
  • The publication titled Clinical validation of a blood-based predictive test for stratification of response to tumor necrosis factor inhibitor therapies in rheumatoid arthritis patients was published in Network and Systems Medicine .
  • PrismRA uses whole blood gene expression data to identify if a patients molecular disease biology is suited to TNFi therapy.
  • About 90% of patients with rheumatoid arthritis are prescribed TNFi therapy after failing disease-modifying anti-rheumatic drugs (DMARDs), such as methotrexate.
  • However, a majority of patients fail to achieve a clinically meaningful change, said Dr. Slava Akmaev, Chief Technology Officer of Scipher Medicine.